Insmed (INSM) stock led a biotech rally Thursday, catapulting 30% on solid second-quarter sales for its new lung disease drug, Brinsupri. First, Brinsupri — a treatment for non-cystic fibrosis bronchiectasis — walloped sales expectations, generating $309.2 million vs. forecasts for $276.6 million, according to FactSet. Then, Insmed raised its guidance for the drug this year to $1.25 billion to $1.4…
Copyright ©2026 Investor’s Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8